Diosgenone synthesis, anti-malarial activity and QSAR of analogues of this natural product

Article abstract of DOI:10.3390/molecules18033356

Solanum nudum Dunal steroids have been reported as being antimalarial compounds; however, their concentration in plants is low, meaning that the species could be threatened by over-harvesting for this purpose. Swern oxidation was used for hemisynthesis of diosgenone (one of the most active steroidal sapogenin diosgenin compounds). Eighteen structural analogues were prepared; three of them were found to be more active than diosgenone (IC₅₀ 27.9 μM vs. 10.1 μM, 2.9 μM and 11.3 μM). The presence of a 4-en-3-one grouping in the A-ring of the compounds seems to be indispensable for antiplasmodial activity; progesterone (having the same functional group in the steroid A-ring) has also displayed antiplasmodial activity. Quantitative correlations between molecular structure and bioactivity were thus explored in diosgenone and several derivatives using well-established 3D-QSAR techniques. The models showed that combining electrostatic (70%) and steric (30%) fields can explain most variance regarding compound activity. Malarial parasitemia in mice became reduced by oral administration of two diosgenone derivatives.

Full text of DOI:10.3390/molecules18033356

Molecules 2013, 18, 3356-3378; doi:10.3390/molecules18033356
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Diosgenone Synthesis, Anti-Malarial Activity and QSAR of
Analogues of This Natural Product
Adriana Pabón 1,2, Gustavo Escobar 3, Esteban Vargas 3, Víctor Cruz 4, Rafael Notario 5,
Silvia Blair 1 and Fernando Echeverri 3,*
1
Grupo Malaria, Facultad de Medicina, Universidad de Antioquia, 050010 Medellín, Colombia;
E-Mails: apabon72@gmail.com (A.P.); silviablair@gmail.com (S.B.)
2
Programa de Biología, Facultad de Ciencias Básicas, Universidad del Atlántico,
080001 Barranquilla, Colombia
3
Grupo de Química Orgánica de Productos Naturales, Instituto de Química,
Universidad de Antioquia, 050010 Medellín, Colombia;
E-Mails: gescobar104@yahoo.es (G.E.); estebanvargas7@gmail.com (E.V.)
4
Instituto de Estructura de la Materia, CSIC, 28006 Madrid, Spain;
E-Mail: victor.cruz@iem.cfmac.csic.es
5
Instituto de Química-Física Rocasolano, CSIC, 28006 Madrid, Spain; E-Mail: rnotario@iqfr.csic.es
* Author to whom correspondence should be addressed; E-Mail: echeveri@udea.edu.co or
feche@une.net.co; Tel.: +574-219-6565.
Received: 15 January 2013; in revised form: 6 March 2013 / Accepted: 7 March 2013 /
Published: 14 March 2013
Abstract: Solanum nudum Dunal steroids have been reported as being antimalarial
compounds; however, their concentration in plants is low, meaning that the species could
be threatened by over-harvesting for this purpose. Swern oxidation was used for
hemisynthesis of diosgenone (one of the most active steroidal sapogenin diosgenin
compounds). Eighteen structural analogues were prepared; three of them were found to be
more active than diosgenone (IC50 27.9 μM vs. 10.1 μM, 2.9 μM and 11.3 μM). The
presence of a 4-en-3-one grouping in the A-ring of the compounds seems to be
indispensable for antiplasmodial activity; progesterone (having the same functional group
in the steroid A-ring) has also displayed antiplasmodial activity. Quantitative correlations
between molecular structure and bioactivity were thus explored in diosgenone and several
derivatives using well-established 3D-QSAR techniques. The models showed that
combining electrostatic (70%) and steric (30%) fields can explain most variance regarding

Molecules 2013, 18
compound activity. Malarial parasitemia in mice became reduced by oral administration of
3357
two diosgenone derivatives.
Keywords: malaria; natural product; steroid; diosgenone; structural analogue; animal model
1. Introduction
Malaria is a parasitic disease which is responsible for about one million deaths annually [1]; its high
morbidity and mortality affects more than 106 countries, in which there were nearly 216 million
episodes of malaria in 2010 alone. There is a compelling need to look for new strategies for treating
malaria [2] considering the above and first-line drugs’ high failure rates (i.e., chloroquine,
amodiaquine, sulfadoxine/pyrimethamine) [3]; therefore compounds having new mechanisms of action
and less (or no) adverse effects are urgently needed. It is well-recognized that natural products
represent a source of new drugs and several properties, including flavonoids, alkaloids (i.e., quinine),
coumarins, quinines, terpenes and lactones (i.e., artemisinins) [4].
It has been reported that diosgenone (2) and several steroid derivatives isolated from Solanum
nudum Dunal having a 4-en-3-one system, such as SN-1 (3) and SN-2 (4) (Figure 1), have
antiplasmodial activity against FcB-2 chloroquine-resistant strains [5–7]. Only a few reports
concerning antiplasmodial activity of steroids could be found in the literature, in spite of the fact that
some steroidal alkaloids are active against malaria [8].
Figure 1. Structure of diosgenin and diosgenone, SN-1 and SN-2 S. nudum sapogenin.
S. nudum steroidal compounds’ antiplasmodial activity and their lack of mutagenicity,
clastogenicity [9,10] and cytotoxicity [11] have substantiated this plant’s potential use in anti-malarial
medication and encouraged attempts to search for new pharmacophores and more active compounds
than diosgenone. The presence of an enone structure in the A-ring and a spirostane in the E-ring were
thus select to generate a series of derivatives as potential antimalarial products. However, diosgenone
is only present in the plant in terms of a few milligrams per kilogram of plant material; obtaining it by
hemisynthesis from commercial diosgenin was thus deemed reasonably logical and would also lead to
obtaining a further series of derivatives.

Molecules 2013, 18
3358
Natural compounds’ synthesis is complex due to the presence of several functional groups in the
side chain and D-ring; diosgenone hemisynthesis from diosgenin was thus a sound alternative for
determining its structure-activity relationship and carrying out studies of its in vivo activity, absorption
and toxicity. Since the synthesis of other compounds involving only diosgenone A- and B-rings is
expected to yield new types of antimalarial substances, diosgenone and some diosgenin steroid
derivatives were obtained and their antiplasmodial potential determined.
A preliminary structure-activity relationship was established and quantitative structure-activity
relationship (QSAR) studies determined correlations between molecular structure and biological
activity. This involved using 3D quantitative structure activity relationship (3D-QSAR) [12], a
well-established drug design methodology providing information regarding statistical correlations
between molecular structure descriptors and experimentally-measured bioactivity [13]. The partial
linear squares (PLS) [14] algorithm provided a solid mathematical background for 3D-QSAR for
statistically-significant models having acceptable predictive capability, ensured by very conservative
cross-validation testing. This chemometric tool has been used for studying the leishmanicidal activity
of some acnistins and withajardins [15]. 3D-QSAR models have provided detailed structural
information about the factors best explaining the variance observed in experimental bioactivity data.
2. Results and Discussion
2.1. Chemical Transformation
Diosgenone (2) was obtained from diosgenin (1) through a Swern oxidation [16]; the double bond
was then isomerized with oxalic acid in a two-step procedure in a one-pot reaction (84%). This type of
reaction has been reported for other compounds and resembles the primary transformation of steroidal
sapogenins into progesterone [17].
Nine diosgenone analogues (compounds 7–15) and five analogues of diosgenin (compounds 16–20)
were synthesized (Scheme 1). These fourteen derivatives were synthesized through several structural
modifications to the A- and B-rings and in the diosgenin (
1) and diosgenone (2) spiroketal system.
Derivatives 7 and were prepared by adding Grignard reagents (Me, Bn, Scheme 2) to compound
8
2; compound 9 was produced by adding p-toluenesulfonic hydrazine. Treating the double bond with
H2O2 produced compound 10 as a non-isolable 2:1 mixture (according to NMR spectra) of  and
-epoxides. Hydrogenation in Pd/C and reduction with NaBH4 yielded compounds 11 and 13.
Compound 12 was obtained from 2 with an excess of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) in
refluxing toluene, while Oxone® (potassium peroxymonosulfate) treatment of 2 in basic media
produced 14, in turn transformed into 15 with TMSI.
Five derivatives were also prepared from diosgenin 1; Compound 16 was obtained with acetic
anhydride and epoxidation with H2O2 produced compound 17, while treatment with excess PCC
produced 18 and a Clemmensen reduction yielded 19. Derivative 20 was produced after treating 1 with
acetic anhydride and zinc chloride [18] (Scheme 2).
Four other derivatives were prepared from compound SN-1 (3). Compound 21 was obtained by
Swern oxidation, 22 through a hydrogenolysis reaction with Pd/C as catalyst, while 23 was the product
of acetylation with excess acetic anhydride and 24 was obtained after reduction with NaBH4 in

Molecules 2013, 18
3359
methanol at room temperature, unfortunately it was not possible to assign the diastereoisomeric ratio
(Scheme 3). Derivative 25 was produced from SN-2 (4) with another Swern oxidation.
Scheme 1. Diosgenone (2) and derivatives 7–15 prepared by modifications made in the A-
and B-rings and the spiroketal system.

Molecules 2013, 18
Scheme 2. Diosgenin derivatives 16–20 obtained by modifications made to the A- and
3360
B-rings. Diosgenin (1).
a
AcO
HO
16
b
c
O
17
O
O
O
O
18
HO
1
d
O
19
O
e
OAc
20
AcO
Scheme 3. SN-1 derivatives 21–24 produced by modifications made to the side chain and
A-ring. SN-1 (3).

Molecules 2013, 18
3361
2.2. Antiplasmodial Activity
The anti-plasmodium activity of 25 derivatives, including progesterone (5) and 17-OH progesterone
(6), was assayed in two P. falciparum strains (Table 1); this analysis was based on the dose inhibiting
50% of parasite growth (IC50) expressed in the FcB2 (chloroquine-resistant) and NF-54 P. falciparum
strains (sensitive to chloroquine, amodiaquine, quinine and artesunate but mefloquine-resistant).
Table 1. In vitro biological activity of derivatives regarding Plasmodium falciparum FCB-2
and NF-54 strains and on HepG2A (human hepatoma cell line).
IC50 μM ± SD
Compound
RI *
CC50 μM
SI **
FCB-2
NF-54
O
E
O
C
D
1
2
3
>482.4
>482.4
1.0
1111.4
2.3
A
B
HO
27.9 ± 5.5
35.4 ± 2.2
0.8
0.6
265.1
60.00
9.5
2.8
21.35 ± 0.2
32.96 ± 0.8
4
5
222.8 ± 12.3
38.2 ± 1.2
248.0 ± 5.3
25.4 ± 1.6
0.9
1.5
2145.7
193.0
9.6
5.0
6
>302.6
>302.6
1.0
>1145
3.8
7
8
70.4 ± 5.5
>396
34.6 ± 3.3
>396
2.0
1.0
216.7
3.1
7.8
>1981
9
56.1 ± 0.3
56.7 ± 6.3
52.5 ± 7.7
1.1
0.5
>1166.6
100.6
30.7
1.8
10
105.7 ± 7.7
11
12
13
>482.4
>482.4
1.0
1.2
0.9
>916.3
>487
1.9
6.6
36.0 ± 2.3
63.2 ± 0.3
29.2 ± 1.1
71.9 ± 0.3
>2411
38.2

Molecules 2013, 18
3362
Table 1. Cont.
IC50 μM ± SD
Compound
RI *
CC50 μM
SI **
FCB-2
NF-54
14
15
10.1 ± 1.3
8.5 ± 2.3
2.2 ± 0.4
1.2
153.4
15.2
31.1
O
O
I
2.9 ± 0.3
1.3
90.2
O
16
17
>438.0
>409.3
>438.0
183.8
1.0
2.2
>2,189.9
>2,046.5
5.0
5.0
18
19
11.3 ± 1.6
9.8 ± 1.0
1.2
1.2
191.5
16.9
6.5
438.2 ± 12.0
369.6 ± 8.3
>2,521.4
20
>379.7
>379.7
1.0
>1,898.6
5.0
21
22
23
92.2 ± 12.3
94.2 ± 5.3
17.3 ± 1.4
70.8 ± 0.8
62.1 ± 8.9
0.6 ± 0.9
1.3
1.5
424.3
82.4
4.6
0.9
28.8
280.8
16.2
24
25
95.0 ± 7.3
122.6 ± 12.8
0.157 ± 0.01
100.9 ± 9.9
95.9± 8.3
0.9
1.3
7.9
306.5
45.2
97.2
3.2
0.4
CQ
0.02 ± 0.005
486.0
AF-B
39.6
* RI (resistance index) = IC50 FCB-2 (resistant strain)/IC50 NF-54 (sensitive strain); ** SI (selectivity index)
= CC50 HepG2/IC50 parasite FCB-2; CQ: chloroquine (control of antiplasmodial assays); AF-B: amphotericin
B (positive control of cytotoxicity assays).

Molecules 2013, 18
3363
Table 1 shows IC50, CC50 (50% cytotoxic dose in HepG2-A16 cells), selectivity index (SI = IC50/CC50)
and resistance index values (RI = IC50 FCB-2/IC50 NF-54) for all compounds. Chloroquine had IC50
157.9 nM in the FCB-2 strain and IC50 20 nM in the NF-54 strain. Diosgenin (1) lacked antiplasmodial
activity since its IC50 was >482.4 µM against P. falciparum; however, diosgenone (2) was active,
having IC50 27.9 µM in the FcB-2 strain and 35.4 µM IC50 in the NF-54 strain.
Compounds 7, 9, 10 and 13 had marginal activity compared to diosgenone and 12 had similar
activity to diosgenone, though derivatives 8 and 11 were inactive against both P. falciparum strains.
Compounds 14 and 15 had high antiplasmodial activity (IC50 10.1 µM and 2.9 µM, respectively), and
high SI (15.2 and 31.1, respectively). Compounds 16, 17, 19 and 20 were neither active nor toxic.
However, more active compound 15 was very unstable since solution color in NMR tube changed
from clear to deep brown, so its effect on P. berghei was not evaluated (iodine being generated during
decomposition may have been responsible for such activity). Regarding RI, it was found that
derivatives 2, 3, 4, and 10 had values below zero, indicating better antiplasmodial activity in
chloroquine-resistant parasites.
The importance of anunsaturated system in the molecules’ A-rings (exhibiting antiplasmodial
activity) was demonstrated when the 3-en-1-one system was modified in diosgenone by hydrogenation
or reduction (derivatives 7–13, but not 12). Such a system is present in progesterone 5, a compound
exhibiting antiplasmodial action (IC50 38.2 µM), but lacking a spiroketal system; however, 17-OH
progesterone 6 was an inactive compound. Compound 18 (having two carbonyl groups) was more
active than diosgenone, indicating this system’s importance regarding antiplasmodial activity.
SN-1 derivatives (3), 21–24 had a lower antiplasmodial effect than that of the natural compound
(IC50 21.4 µM) but, surprisingly, diacetate 23 (IC50 17.3 µM) was more active in the FCB-2 strain
(16.2 SI), as well as being less toxic.
The Plasmodium berghei-infected mice model was used as a biological model for in vivo
antimalarial tests; more active, stable, less cytotoxic compounds 14 and 18 were selected to establish
in vivo effects. Antimalarial activity was expressed as the percentage of parasite multiplication
inhibition. This assay found that all mice, except one, had an average 0.4% infected erythrocytes 24 h
post-infection, at which time treatment was started with 100 mg/kg weight of the derivative or 5 mg/kg
weight of CQ.
Regarding mortality, all mice were alive until termination of the experiment (day 5) when they were
then anesthetized and sacrificed. CQ-treated mice had 100.0% reduction of parasitemia on the second
day of treatment; by contrast, mice treated with diosgenone (2) showed no decrease in the amount of
parasites, reaching 50.0% parasitaemias on the fifth day post treatment. Such parasitemia was higher
than that found in treated mice or untreated controls with the vehicle, reaching rates of 36.0%
parasitized erythrocytes. Treating mice with derivatives 14 and 18 caused a therapeutic effect, leading
to 36.7% and 35.0% reduction in parasitemia, respectively (Figure 2). Their low solubility in water and
organic solvents must be considered (given that this concentration was relatively high), since there would
have been reduced gastrointestinal absorption which could have affected an optimal therapeutic dose.

Molecules 2013, 18
Figure 2. Percentage parasitemia inhibition in P. berghei-infected mice following
3364
treatment with derivatives 14 and 18.
100
80
60
40
20
CQ
Diosgenone (2)
Derivative 14
Derivative 18
0
0
2
4
6
Days of monitoring
It would also be interesting to evaluate these drugs’ therapeutic effect using a chronic model of
malaria (such as Plasmodium chabaudi). A striking finding emerged on the third day of treatment with
both derivatives during the above experiments; many P. berghei sexual forms became reduced, along
with asexual parasitaemia on the fourth day of treatment. It may be thought that S. nudum steroid
derivatives act similarly to progesterone (unsaturated system) in inducing differentiation into
gametocytes of asexual parasites. Lingnau et al. [19] treated P. falciparum cultures with different
concentrations of insulin, progesterone, 17--estradiol and testosterone, finding that insulin asexual
in vitro density increased compared to controls. By contrast, parasitemia did not increase when adding
steroidal hormones progesterone, 17--estradiol and testosterone asexual, but gametocyte development
was much more pronounced when using these steroids in the treatment, mainly progesterone.
2.3. Molecular Modeling
3D-QSAR analysis followed the methodology described in Section 4.3 of this manuscript. The best
model obtained after PLS analysis was a mixture of 70% electrostatic field and 30% steric field. Cross-
validated correlation coefficient q2 was 0.63, with 0.447 log units standard error of prediction at two
components. This q2 value (greater than 0.5) indicated that a good predictive model had been obtained,
in accordance with usual practice in the 3D-QSAR field. Compounds 4, 11, 21, 22 and 25 behaved as
statistical outliers; this was probably due to the conformational variability associated with the D-ring
substituents’ flexible chains introducing additional noise to the model. These compounds also had low
to moderate bio-activity so their contribution to the model would not have been expected to have been
very significant.
The QSAR model was better depicted as 3D isosurfaces having standard deviation (stdev)
multiplication values regarding the QSAR coefficient (coeff) at each point. This field gave information
concerning the model’s salient features, specified by QSAR coefficients’ magnitude, scaled by
associated variability at each grid point, specified by standard deviation [12].

Molecules 2013, 18
3365
Figure 3 presents a stdev*coeff field contoured on compound 15; electrostatic and steric
contributions are conveniently separated. Increased negative charge can be observed around steroidal
skeleton A-, B- and D-rings (red mesh in Figure 3), associated with improved bio-activity, whereas
increased positive charge around the D-ring decreased bio-activity.
Figure 3. Electrostatic and steric contours mapped onto compound 15.
B
A
A: Electrostatic field; B: Steric field. Electrostatic field - red and blue mesh surfaces; Steric field - yellow and
green mesh surfaces; Two orientations are shown in the upper and lower parts of the Figure.
Regarding steric contribution, increased steric volume beyond the D-ring (green mesh) correlated
with positive contribution to bioactivity, whereas the yellow mesh around the A-ring meant negative
steric field contribution to bioactivity.
The fitting statistics for this model had a 0.958 correlation coefficient (estimated 0.1510 g units
standard error). A comparison of the actual plot to the predicted one, showed the good correlation
obtained. However, it should be mentioned that the standard error for the prediction given above only
came from the statistical information provided by the model.
It could be assumed from such observations that the steroidal skeleton provided a rigid framework
having the right shape to accommodate specific electrostatic interactions with charged residues at the
receptor’s active site, leaving room for an additional increase in steric volume beyond the D-ring.
3. Experimental
3.1. Chemistry
3.1.1. General Procedures
S. nudum steroid isolation and purification have already been described [5,6]; this involved
reactions in an anhydrous nitrogen atmosphere using freshly-distilled, dry solvents prepared by
standard methods. 4-Pregnene-3,20-dione, progesterone (5) and 17-hydroxy-4-pregnene-3,20-dione (6)
were purchased from Sigma (St. Louis, MO, USA). Silica gel 60 (E. Merck, 70–230 mesh) was used
for column chromatography purification. Thin-layer chromatography and nuclear magnetic resonance

Molecules 2013, 18
3366
(NMR) were used for checking all new compounds’ purity. All reactions were monitored by TLC
analysis on pre-coated silica gel F254 plates (E. Merck). Melting points (uncorrected) were determined
by electrothermal equipment (Electrothermal 3100) and a spectrometer was used for infrared (IR)
analysis (Thermo Nicolet Avatar 330 FT-IR, DTGS KBr). A spectrometer (Bruker AC 300) recorded
13
1
1H-, C- and H-decoupled spectra at 300 and 75 MHz. Chemical shifts () obtained in CDCl3 were
reported per million (ppm) relative to the residual solvent proton (7.26 ppm) and carbon signals (77.2).
Only assignable signals were listed. Low resolution mass spectra were obtained in positive mode
electrospray ionization mass spectra (ESI-MS) coupled to high-performance liquid chromatography
(HPLC) apparatus (Agilent series 1200 model VL, Palo Alto, CA, USA) equipped with an atmospheric
pressure ionization source.
3.1.2. Chemical Transformations
The pertinent literature contains very few publications regarding diosgenone synthesis; these have
dealt with the Oppenauer reaction with aluminum alkoxides [20], or ruthenium complexes [21].
However, yields have been poor or absent. Enzymatic transformations have also been attempted with
structurally-similar molecules [22,23]. Obtaining diosgenone via Swern oxidation with subsequent
double bond isomerization with oxalic acid in refluxing ethanol is reported here (84% overall yield).
(25R)-4-Spirosten-3-one, diosgenone (2). A mixture of oxalyl chloride (1.08 mmol, 136 mg, 2 eq.) in
dichloromethane (DCM, 5 mL) was treated with dimethyl sulfoxide (DMSO, 0.23 mL, 1.08 mmol, 84 mg,
2 eq.) in DCM (5 mL) and stirred at −60 °C for 5 min. (25R)-5-spirosten-3β-ol (3β-hydroxy-5-
spirostene, diosgenin 1, 300 mg, 0.72 mmol, 1 eq.) in DCM (20 mL) was then added to the reaction
mixture. Temperature was allowed to reach −10 °C after 20 min and then 0.65 mL N,N-diisopropyl
ethylamine (3.73 mmol, 482 mg, 5.2 eq.) were added; stirring was continuous for 1 h to reach room
temperature (RT) and HCl (20 mL, 5%) was added. The combined organic layer was washed with an
aqueous solution (aq) of NaHCO3 (30 mL), dried (Na2SO4) and evaporated under reduced pressure.
The residue was dissolved in an oxalic acid solution (1.4 g, 15.5 mmol, 21.5 eq.) in ethanol (20 mL)
and heated to reflux for 5 h, extracted with DCM (3 × 15 mL), dried (Na2SO4) and evaporated under
reduced pressure. The residue was purified by chromatography on silica and eluted with 4:1:1
hexane/DCM/Ethyl acetate (EtOAc), yielding diosgenone (2), as a white solid (255 mg, 84%), Rf = 0.6
1
(hexane/EtOAc 4:1). Melting point (m.p.): 188–190 °C. IR (KBr): 2950, 1680, 1470. H- NMR
(CDCl3) δ: 5.6 (s, 1H, H-4), 4.3 (dd, J1 = 14.0 Hz, J2 = 7.0 Hz, 1H, H-16), 3.4 (dd, J1 = 11.0 Hz,
J2 = 3.0 Hz, 1H, H-26), 2.5 (dt, J1 = 17.0 Hz, J2 = 7.0 Hz 1H, H-2), 2.4 (dt, J1 = 15.0 Hz, J2 = 12.0 Hz,
1H, H-2), 1.12 (s, 3H, H-19), 0.88 (d, J = 7.0 Hz, 3H, H-21), 0.76 (s, 3H, H-18), 0.72 (d, J = 6.3, 3H,
13
H-27); C-NMR (CDCl3) δ: 199.3 (C-3), 171.0 (C-5), 123.7 (C-4), 109.1 (C-22), 80.4 (C-16), 66.7
(C-26), 61.9 (C-17), 55.5 (C-14), 53.6 (C-9), 41.5 (C-20), 40.2 (C-13), 39.5 (C-12), 38.5 (C-10), 35.5
(C-1), 35.0 (C-8), 33.8 (C-2), 32.6 (C-6), 32.0 (C-7), 31.6 (C-15), 31.2 (C-23), 30.1 (C-25), 28.6 (C-24),
20.7 (C-11), 17.2 (C-19), 17.0 (C-27). 16.2 (C-18), 14.4 (C-21). MS (m/z) (%): 413.0 (M+, 100).
(25R)-3-Methyl-spirostan-2,4-diene (7). Diosgenone (2, 25 mg, 0.6 mmol, 1 eq.) in diethyl ether (5 mL)
was treated with methyl magnesium bromide solution (0.44 mL, 0.62 mmol, 1.1 eq., 1.4 M
toluene/THF 3:1) and stirred at −15 °C (one hour) followed by 2 h at RT. The reaction mixture was

Molecules 2013, 18
3367
slowly treated with 5% aq NH4Cl (20 mL) and extracted with three  20 mL portions of DCM. The
combined organic extract was washed with water (20 mL) and brine (20 mL). The dried (Na2SO4)
organic phase was concentrated under reduced pressure. The residue was purified by chromatography
on a silica gel column (DCM/hexane 8:1) yielding compound 7 (14 mg, 54%): Rf = 0.4 (DCM). M.p.:
172–174 °C. IR (KBr): 2928. 1H-NMR (CDCl3) δ: 5.8 (s, 1H, H-4), 5.4 (dd, J = 5.0 Hz, 1H, H-2), 4.4
(dt, J1 = 7.9 Hz, J2 = 1.8 Hz, 1H, H-16), 3.5 (d, J = 10.7 Hz, 2H, H-26), 1.7 (s, 3H, Me), 1.0 (s, 3H, H-19),
0.9 (d, J = 7.1 Hz, 3H, H-21), 0.8 (s, 3H, H-18), 0.72 (d, J = 6.3, 3H, H-27);13C-NMR (CDCl3) δ:
142.0 (C-5), 133.4 (C-3), 130.4 (C-2), 124.8 (C-4), 120.9 (C-6), 109.7 (C-22), 81.3 (C-16), 67.3 (C-26),
62.5 (C-17), 57.1 (C-14), 48.7 (C-9), 40.8 (C-20), 40.3 (C-13), 32.1 (C-6), 32.0 (C-15), 31.9 (C-23),
31.8 (C-25), 28.9 (C-24), 28.3 (C-11), 24.3 (Me), 21.3 (C-18), 19.4 (C-27), 16.8 (C-18), 14.9 (C-21).
MS (m/z) (%): 411.2 (M+, 10).
(25R)-3-Benzyl-spirostan-4-en-3-ol (8). Diosgenone (2, 50 mg, 0.12 mmol, 1 eq.) in diethyl ether (5 mL)
was treated with benzylmagnesium bromide solution (0.14 mL, 0.14 mmol, 1.1 eq., 1.0 M THF) and
treated as above. The residue was purified by chromatography on a silica gel column (DCM/hexane
8:1) yielding compound 8 as a white solid (56 mg, 92%): Rf = 0.4 (hexane/EtOAc 8:1). M.p.: 203–205 °C.
IR (KBr): 2930, 2880, 1600–1700. 1H-NMR (CDCl3) δ: 7.40–7.09 (m, 5H, H-Ar), 5.1 (s, 1H, H-4), 4.4
(dt, J1 = 7.9, J2 1.7 Hz, 1H, H-16), 3.4 (d, J = 10.7 Hz, 2H, H-26), 2.8 (d, J = 14.7 Hz, 2H, Ar-CH2),
1.1 (s, 3H, H-19), 1.0 (d, 7.1 Hz, 3H, H-21), 0.8 (s, 3H, H-18), 0.8 (d, J = 6.2 Hz, 3H, H-27); 13C-NMR
(CDCl3) δ: 146.8 (C-1'), 137.7 (C-5), 131.1 (C-4'), 129.3 (C-3', C-5'), 126.8 (C-2', C-4'), 126 (C-4),
109.7 (C-22), 81.2 (C-16), 71.7 (C-3), 67.3 (C-26), 62.5 (C-17), 56.4 (C-14), 54.8 (C-9), 47.2 (C-20),
40.3(C-13), 32.2 (C-6), 32.1 (C-15), 31.2 (C-22), 30.1 (C-25), 29.2 (C-26), 29.1 (C-10), 28.6 (C-23),
28.4 (C-24), 21.4 (C-19), 20.6 (C-11), 17.5 (C-27), 16.8 (C-18), 14.9 (C-21). MS (m/z) (%): 506.2
(M+ +1, 5), 487.2 (86).
(25R)-3-p-Toluenehydrazine-spirostan-4-ene (9). A mixture of diosgenone (2, 102 mg, 0.25 mmol, 1 eq.)
and pTsNHNH2 (118 mg, 0.65 mmol, 2.6 eq.) in ethanol (5 mL) was heated to reflux for 5 h. The
solvent was evaporated under vacuum and the residue was purified by chromatographic column on
silica gel (hexane/EtOAc 5:1) yielding compound 9 as a white solid (122 mg, 84%): Rf = 0.45
(hexane/EtOAc 5:1). M.p.: 148–150 °C. IR (KBr): 3508, 2930. 1H-NMR (CDCl3) δ: 7.9 (d, J = 8.1 Hz,
2H, H-Ar), 7.3 (d, J = 8.1 Hz, 2H, H-Ar), 5.8 (s, 1H, H-4), 4.4 (dt, J1 = 7.9 Hz, J2 = 1.8 Hz, 1H, H-16),
3.4 (d, J = 10.7 Hz, 2H, H-26), 2.4 (s, 3H, Ar-CH3), 1.0 (s, 3H, H-19), 0.9 (d, J = 7.2 Hz, 3H, H-21),
0.76 (s, 3H, H-18), 0.7 (d, J = 6.3 Hz, 3H, H-27); 13C-NMR (CDCl3) δ: 145.0 (C-5), 142.6 (C-3), 139.8
(C-1'), 136.4 (C-4'), 129.9 (C-3', C-5'), 129.1 (C-4), 128.5 (C-3', C-5'), 120.8 (C-2', C-6'), 109.7 (C-22),
81,6 (C-16), 62.5 (C-26), 56.2 (C-17), 53.9 (C-14), 42,3 (C-20), 35.7 (C-8), 29.2 (C-23), 29.0 (C-10),
28.8 (C-1), 28.7 (C-2), 28.5 (C-15), 28.4 (C-6), 28.2 (C-25), 28.1 (C-24), 20.8 (C-11), 20.6 (C-Me)
17.5 (C-19), 16.7 (C-27), 14.9 (C-21), 14.5 (C-18), 14.1 (C-21). MS (m/z) (%): 581.3 (M+, 5); 539.1 (36).
(25R)-4,5-Epoxy-spirostan-3-one (10). A mixture of diosgenone (2, 30 mg, 0.073 mmol, 1 eq.) and
hydrogen peroxide (0.5 mL, 30%, 4.9 mmol, 67 eq.) in DCM/acetone 1:1 (20 mL) was treated with
NaOH (1 mL, 2%) and stirred at RT for 48 h; then water was added to the reaction mixture and
extracted with ethyl acetate (2 × 15 mL). The combined organic layer was washed with an aq NaHCO3

Molecules 2013, 18
3368
solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. The residue was purified by
chromatography on a silica gel column (hexane/EtOAc 10:1) yielding compound 10 as a white solid
corresponding to the mixture of epoxides α (70%) y β (30%) (21 mg, 65%): Rf = 0.6 (hexane/EtOAc
9:1). M.p.: 184–186 °C. IR (KBr): 2899, 1715. 1H-NMR (CDCl3) δ: 4.4 (dt, J1 = 7.9 Hz, J2 = 1.8 Hz,
1H, H-16), 3.3 (d, J = 10.7 Hz, 2H, H-26), 3.0 (s, 1H, H-4), 2.9 (s, 1H, H-4), 1.2 (s, 3H, H-19), 1.0
(d, J = 7.1 Hz, 3H, H-21), 0.8 (s, 3H, H-18), 0.8 (d, J = 6.2 Hz, 3H, H-27); 13C-NMR (CDCl3) δ: 207.2
(C-3), 109.7 (C-22), 82.0 (C-16), 70.5 (C-5), 67.3 (C-26), 63.3 (C-4), 63.2 (C-17), 60.4 (C-17), 55.8
(C-14), 48.1 (C-9), 40.6 (C-12), 35.2 (C-20), 35.0 (C-17), 34.5 (C-8), 34.5 (C-10), 34.0 (C-2), 32.4 (C-1),
31.5 (C-15), 30.7 (C-6), 28.9 (C-23), 28.5 (C-7), 27.4 (C-24), 21.1 (C-11), 16.9 (C-27), 16.2 (C-19),
15.1 (C-21), 14.6 (C-18). MS (m/z) (%): 429.2 (M+, 82), 427.2 (12).
(25R)-Spirostan-3-one (11). A mixture of diosgenone (2, 40.8 mg, 0.1 mmol, 1 eq.) and palladium on
carbon (Pd/C) 10% (2.0 mg, 10% mol, 0.01 mmol) in EtOAc (5 mL) was treated with hydrogen and
stirred at RT overnight. The reaction mixture was filtered through a pad of celite and the solvent was
evaporated under reduced pressure. The residue was purified by chromatography on a silica gel
column (hexane/EtOAc 10:1) yielding compound 11 as a white solid (35 mg, 85%): Rf = 0.4
(hexane/AcOEt 10:1). M.p.: 153–155 °C. IR (KBr): 2929, 1712. 1H-NMR (CDCl3) δ: 4.4 (dt, J1 = 7.9 Hz,
J2 = 1.8 Hz, 1H, H-16), 3.4 (d, J = 10.7 Hz, 2H, H-26), 2.6 (d, J = 15.1 Hz, 2H, H-4), 1.1 (dt, J1 = 7.6 Hz,
J2 3.6 Hz, 2H, H-6), 1.0 (s 3H, H-18), 0.9 (d, J = 7.0 Hz, 3H, H-21), 0.7 (d, J = 6.3 Hz, 3H, H-27);
13C-NMR (CDCl3) δ: 210.0 (C-3), 109.7 (C-22), 81.2 (C-16), 67.3 (C-26), 62.6 (C-17), 56.7 (C-14),
44.6 (C-4), 41.1 (C-20), 40.3 (C-13), 38.9 (C-12), 38.2 (C-1), 38.1 (C-2), 35.8 (C-10), 35.0 (C-8), 31.6
(C-15), 30.7 (C-23), 28.6 (C-24, C-6), 20.8 (C-11), 19.9 (C-27), 17.5 (C-21), 16.8 (C-18), 14.9 (C-19).
MS (m/z) (%): 415.2 (M+, 86), 397.1 (6).
(25R)-1,4-Spirostadien-3-one (12). A mixture of diosgenone (2, 50.0 mg, 0.1 mmol, 1 eq.), benzoic
acid (14.8 mg, 0.12 mmol, 1.1 eq.) and 2,3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ, 40.9 mg,
0.18 mmol, 1.8 eq.) was dissolved in 10.0 mL toluene and then heated to reflux for 12 h. The reaction
mixture was filtered through celite and the solvent was evaporated under reduced pressure. The residue
was purified by chromatography on a silica gel column (hexane/DCM/EtOAc 4:1:1) yielding
compound 12 as a white solid (30 mg, 60%): Rf = 0.3 (hexane/AcOEt 10:1). M.p.: 181–183 °C. IR
1
(KBr): 2933, 2854, 1664, 1458. H-NMR (CDCl3) δ: 7.1 (d, J = 10.0, 1H, H-1), 6.3 (d, J = 10.0, 1H,
H-2), 6.1 (s, 1H, H-4), 4.4 (dt, J1 = 7.9 Hz, J2 = 1.8 Hz, 1H, H-16), 3.6(d, J = 10.7 Hz, 2H, H-26), 2.6
(dt, J1 = 14.4, Hz J2 = 12.0 Hz, 2H, H-6), 1.3 (s, 3H, H-19), 0.9 (d, J = 7.1 Hz, 3H, H-21), 0.8 (d,
J = 6.3 Hz, 3H, H-27), 0.7 (s, 3H, H-18); 13C-NMR (CDCl3) δ: 187.1 (C-3), 170.2 (C-5), 156.7 (C-1),
127.8 (C-2), 124.2 (C-4), 109.8 (C-22), 80.9 (C-16), 67.0 (C-26), 62.4 (C-17), 55.2 (C-14), 52.8 (C-9),
44.2 (C-10), 42.1 (C-20), 41.1 (C-13), 39.9 (C-12), 35.6 (C-8), 34.2 (C-7), 33.5 (C-6), 33.1 (C-15),
32.3 (C-23), 31.1 (C-25), 30.7 (C-24), 23.2 (C-11), 19.1 (C-19), 17.6 (C-27), 16.9 (C-18), 14.9 (C-21).
MS (m/z) (%): 411.1 (M+, 100).
(25R)-4-Spirosten-3-ol (13). Diosgenone (2, 24 mg, 0.06 mmol, 1 eq.) in methanol (5 mL) was treated
with NaBH4, (80 mg, 0.2 mmol, 3.3 eq.) and stirred at RT for 2 h overnight; water was then added to
the reaction mixture and extracted with DCM (2 × 15 mL). The combined organic layer was washed

Molecules 2013, 18
3369
with an aq NaHCO3 solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. The
residue was purified by chromatography on a silica gel column (hexane/EtOAc 5:1) yielding
compound 13 as a white solid (21 mg, 65%): Rf = 0.4 (hexane/AcOEt 5:1). M.p.: 116–118 °C. IR
1
(KBr): 3264, 2930, 2846, 1448. H-NMR (CDCl3) δ: 5.3 (d, J = 6.5 Hz, 1H, H-4), 4.4 (dt, J1 = 15.0,
J2 = 7.5 Hz, 1H, H-16), 4.1 (dd, J1 = 18.0 Hz, J2 = 6.5 Hz, 1H, H-3), 3.5–3.3 (d, J = 10.7 Hz, 2H,
H-26), 2.3 (dd, J1 = 14.0 Hz, J2 = 12.0 Hz, 1H, H-6), 1.0 (s, 3H, H-18), 0.9 (d, J = 6.9 Hz, 3H, H-21),
0.8 (s, 3H, H-19), 0.7 (d, J = 6.2 Hz, 3H, H-27); 13C-NMR (CDCl3) δ: 147.8 (C-5), 123.9 (C-4), 109.7
(C-22), 81.2 (C-16), 68.3 (C-3), 67.2 (C-26), 62.5 (C-17), 56.4 (C-14), 54.8 (C-9), 40.8 (C-20), 39.8
(C-13), 39.6 (C-12), 38.4 (C-10), 37.7 (C-1), 35.9 (C-8), 30.7 (C-25), 29.9 (C-2), 29.2 (C-24), 21.2 (C-11),
17.2 (C-19), 16.8 (C-27), 16.2 (C-18), 14.9 (C-21). MS (m/z) (%): 415.2 (M+, 80), 413.2 (21).
(25R)-4,5-Epoxy-spirostan-16α-hydroxy-3-one (14). A mixture of diosgenone (2, 200 mg, 0.48 mmol,
1 eq.) and NaHCO3 (1.89 g, 22.5 mmol, 47 eq.) in CHCl3-acetone-1.0 mM Na2EDTA (1:1:1, 37.5 mL,
4.65 g, 12.5 mmol, 26 eq.) was treated with oxone (6 g, 9.8 mmol, 20.4 eq.) in EDTA-Na2 (1 Mm) and
stirred at RT for 48 h. The reaction mixture was extracted with DCM (2 × 15 mL) and the combined
organic layer was washed with an aq NaHCO3 solution (30 mL), dried (Na2SO4) and evaporated under
reduced pressure. The residue was purified by chromatography on a silica gel column (hexane/DCM
/EtOAc 3:1:1) yielding compound 14 as a white solid corresponding to the mixture of epoxides α
(70%) y β (30%) (170 mg, 80%): Rf = 0.55 (hexane/AcOEt 3:1). M.p.: 145–147 °C. IR (KBr): 3450,
2940, 1710. 1H-NMR (CDCl3) δ: 3.6 (d, J1 = 10.7 Hz, J2 = 8.2 Hz, 2H, H-26), 3.0 (s, 1H, H-4α), 2.97
(s, 1H, H-4β), 1.8 (dd, J1 = 17.6 Hz, J2 = 2.4 Hz, 2H, H-2), 1.5 (d, J = 10.7 Hz, 2H, H-15), 1.0 (d,
13
J = 7.1 Hz, 3H, H-21), 1.0 (s, 3H, H-18), 0.8 (s, 3H, H-19), 0.8 (d, J = 6.2 Hz, 3H, H-27). C-NMR
(CDCl3) δ: 207.7 (C-3), 116.5 (C-22), 111.6 (C-16), 70.8 (C-5), 70.7 (C-3), 68.7 (C-26), 63.3 (C-4),
55.2 (C-17), 51.0 (C-15), 47.0 (C-9), 42.9 (C-15), 40.3 (C-12), 39.4 (C-20), 37.6 (C-8), 33.2 (C-1),
32.7 (C-6), 31.5 (C-23), 30.3 (C-25), 29.8 (C-24), 29.7 (C-1), 29.2 (C-7), 27.2 (C-2), 21.8 (C-11), 20.0
(C-11), 18.0 (C-27), 16.0 (C-19), 15.5 (C-18), 15.0 (C-21). MS (m/z) (%): 445.0 (M+, 3), 427.0 (96).
(25R)-26-Iodine-cholest-4-en-3,16,22-trione (15). A mixture of sodium iodide (NaI, 3 g, 20 mmol, 20 eq.),
TMSCl (0.63 mL, 5 mmol, 5 eq.) and molecular sieve (5 g) in CH3CN (24 mL) was stirred at RT for 2 h.
Compound 9 (446 mg, 1 mmol, 1 eq.) in DCM (15 mL) was added for 20 min. The reaction mixture
was extracted with DCM (2 × 15 mL) and the combined organic layer was washed with an aq NaHCO3
solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. The residue was purified by
chromatography on a silica gel column (hexane/DCM/EtOAc 2:1:1) yielding compound 15 as a white
solid (404 mg, 75%): Rf = 0.4 (hexane/EtOAc 2:1). M.p.: 148–150 °C. IR (KBr): 2942, 1733, 1717.
1H-NMR (CDCl3) δ: 5.7 (s, 1H, H-4), 3.3 (d, J = 4.9 Hz, 2H, H-26), 2.6 (d, J = 8.6 Hz, 1H, H-17), 1.6
(d, J = 16.4 Hz, 2H, H-23), 1.2 (d, J = 12.0 Hz, 3H, H-21), 1.1 (d, J = 6.2 Hz, 3H, H-27), 1.0 (s, 3H,
13
H-18), 0.8 (s, 3H, H-19); C-NMR (CDCl3) δ: 218.2 (C-16), 213.7 (C-22), 199.9 (C-3), 170.8 (C-5),
124.9 (C-4), 66.9 (C-17), 53.9 (C-9), 51.2 (C-14), 44.0 (C-), 42.5 (C-13), 40.2 (C-20), 39.3 (C-12),
39.2 (C-15), 39.0 (C-10), 36.2 (C-23), 36.1 (C-8), 34.6 (C-1), 34.5 (C-24), 33.2 (C-2), 32.7 (C-6), 30.6
(C-7), 21.2 (C-25), 20.9 (C-27), 18.6 (C-11), 18.1 (C-26), 17.6 (C-19), 16.1 (C-21), 13.8 (C-18). MS
(m/z) (%): 539.1 (M+, 96), 500.1 (5).

Molecules 2013, 18
3370
(25R)-3-Acetoxy-spirostan-5-ene (16). A mixture of diosgenine (1, 500 mg, 1.2 mmol, 1 eq.), acetic
anhydride (1 mL, 1.05 mmol, 8.8 eq.) and ZnCl2 (0.5 g, 3.6 mmol, 3 eq.) was stirred at RT for 3 h. An
Na2CO3 solution was added to the reaction mixture and extracted with EtOAc (2 × 15 mL), dried
(Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography on a
silica gel column (hexane/EtOAc/DCM 5:1:1) yielding compound 16 as a white solid (452 mg, 82%)
Rf = 0.5 (hexane/EtOAc 3:1). M.p.: 182–184 °C. 1H-NMR (CDCl3) δ: 5.4 (d, 1H, J = 4.7 Hz, H-6), 4.6
(m, 1H, H-3), 4.4 (dt, 1H, J1 = 15 Hz, J2 = 7 Hz, H-16), 3.5(d, J = 10.7 Hz, 2H, H-26), 2.1 (s, 3H,
3-OCOCH3), 1.6 (s 3H, H-18), 1.0 (s 3H, H-19), 0.9 (d, 3H, J = 7.1 Hz, H-21), 0.8 (d, 3H, J = 6.3 Hz,
H-27); 13C-NMR (CDCl3) δ: 170.5 (3-OCOCH3), 139.6 (C-5), 122.3 (C-6), 109.2 (C-22), 80.8 (C-16),
73.8 (C-3), 66.8 (C-26), 62.0 (C-17), 56.4 (C-14), 49.9 (C-9), 41.6 (C-20), 40.2 (C-13), 39.7 (C-4),
38.0 (C-12), 36.9 (C-1), 36.7 (C-10), 32.0 (C-7), 31.8 (C-15), 31.4 (C-8), 31.3 (C-23), 30.3 (C-25),
28.8 (C-2), 27.7 (C-24), 21.4 (3-OCH3), 20.8 (C-11), 19.3 (C-19), 17.1 (C-27), 16.2 (C-18), 14.5 (C-21).
(25R)-5,6-Epoxy-spirostan-3-ol (17). A mixture of diosgenine (1, 100 mg, 2.0 mmol, 1 eq.) and
NaHCO3 (1.89 g, 22.5 mmol, 11 eq.) in CHCl3-acetone-1.0 mM Na2EDTA (1:1:1, 37.5 mL) was
treated with oxone (6.0 g, 9.8 mmol) in Na2EDTA 1mM and stirred at RT for 16 h. The reaction
mixture was extracted with DCM (2 × 15 mL). The combined organic layer was washed with an aq
NaHCO3 solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. The residue was
purified by chromatography on a silica gel column (hexane/DCM/EtOAc 1:1:1) yielding compound 17
as a white solid corresponding to the mixture of epoxides α (70%) y β (30%) (85.1 mg, 70.1%): Rf = 0.4
1
(hexane/EtOAc 2:3). M.p.: 97–99 °C. H-NMR (CDCl3) δ: 4.38 (dd, 1 H, J = 7.4 Hz, H-16), 3.9 (m,
1H, H-3), 3.5 (dd, 1H, J = 11, 3 Hz, H-26), 3.36 (dd, 1H, J = 11 Hz, H-26), 3.10 (d, 1H, J = 4Hz,
H-6β), 2.92 (d, 1H, J = 4 Hz, H-6α), 1.09 (s, 3H, H-19), 0.97 (d, 3H, J = 7 Hz, H-21), 0.80 (d,3H, J = 6 Hz,
13
H-27), 0.74 (s, 3H, H-18); C-NMR (CDCl3) δ: 110.0 (C-22), 81.3 (C-16), 69.3 (C-3), 67.5 (C-26),
66.4 (C-5), 62.6 (C-17), 59.8 (C-6), 55.7 (C-14), 43.3 (C-4), 42.3 (C-12), 41.0 (C-13), 40.5 (C-20),
35.7 (C-10), 32.4 (C-1), 31.8 (C-15), 31.7 (C-7), 31.0 (C-23), 30.1 (C-9), 30.0 (C-26), 29.7 (C-2), 29.5
(C-24), 22.5 (C-11), 17.0 (C-27), 16.9 (C-19), 16.7 (C-21), 15.2 (C-18).
(25R)-4-Spirosten-3,6-dione (18). A mixture of diosgenine (1, 50 mg, 0.12 mmol, 1 eq.) and
pyridinium chlorochromate (PCC, 100 mg, 0.46 mmol, 3.8 eq.) in DCM (30 mL) was stirred at RT for
5 h. The reaction mixture was extracted with DCM (2 × 15 mL). The combined organic layer was
washed with an aq NaHCO3 solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure.
The residue was purified by chromatography on a silica gel column (hexane/DCM/EtOAc 2:1:1)
yielding compound 18 as a yellow solid (28 mg, 55%): Rf = 0.3 (hexane/AcOEt/DCM 7:1:1). M.p.:
1
200–202 °C. IR (KBr): 2951, 2925, 2850, 1700. H-NMR (CDCl3) δ: 6.2 (s, 1H, H-4), 4.42 (dd,
J1 = 7.6 Hz, J2 = 13.8 Hz, 1H, H-16), 3.5(d, J = 10.7 Hz, 2H, H-26), 2.8 (d, J = 14.7 Hz, 2H, H-7), 1.2
(s, 3H, H-19), 1.0 (d, J = 7.1 Hz, 3H, H-21), 0.8 (d, J = 6.2 Hz, 3H, H-27), 0.7 (s, 3H, H-18);
13C-NMR (CDCl3) δ: 202.1 (C-7), 199.6 (C-3), 160.8 (C-5), 125.9 (C-4), 109.6 (C-22), 80.5 (C-16),
67.2 (C-26), 62.1 (C-17), 56.5 (C-14), 51.1 (C-9), 47.0 (C-7), 41.9 (C-20), 40.7 (C-12), 39.9 (C-13),
39.4 (C-10), 35.7 (C-1), 34.2 (C-2), 33.9 (C-8), 31.7 (C-15), 31.5 (C-23), 30.4 (C-25), 29.0 (C-24),
20.9 (C-11), 17.8 (C-19), 17.3 (C-27), 16.5 (C-18), 14.7 (C-21). MS (m/z) (%): 427.0 (M+, 100).

Molecules 2013, 18
3371
(25R)-3,5-Spirostadiene (19). HCl (2.5 mL, 36.5%, 31.8 mmol, 635 eq.) was added to a solution of
diosgenine (1, 20 mg, 0.05 mmol, 1 eq.), zinc powder (250 mg, 3.8 mmol, 76 eq.) in ethanol (5 mL)
and stirred at RT for 2 h. NaOH (15 mL, 10%) was added to the reaction mixture and extracted with
DCM (2 × 15 mL). The combined organic layer was washed with an aq NaHCO3 solution (30 mL),
dried (Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography
on a silica gel column (DCM/methanol (MeOH) 100:1) generating 19 as white solid (13 mg, 71%):
Rf = 0.5 (DCM/MeOH 20:1). M.p.: 116–118 °C. 1H-NMR (CDCl3) δ 5.9: (d, J = 4.0 Hz, 1H, H-3), 5.8
(d, J = 4.0 Hz, 1H, H-4), 5.3 (dd, J = 6.0, 1.3 Hz, 1H, H-6, 4.39 (dt, J1 = 7.6 Hz, J2 = 13.8 Hz, 1H,
H-16), 3.4 (d, J = 10.7 Hz, 2H, H-26), 1.2 (s, 3H, H-19), 1.0 (d J = 7.1 Hz, 3H, H-21), 0.9
13
(d, J = 6.2 Hz, 3H, H-27), 0.8 (s, 3H, H-18); C-NMR (CDCl3) δ: 141.9 (C-5), 129.3 (C-3), 125.4
(C-4), 123.1 (C-6), 109.7 (C-22), 81.2 (C-16), 67.2 (C-26), 62.5 (C-17), 57.2 (C-14), 48.7 (C-9), 41.8
(C-20), 40.3 (C-12), 35.3 (C-10), 34.6 (C-1), 34.0 (C-8), 33.7 (C-15), 33.4 (C-23), 32.0 (C-8), 30.6
(C-25), 28.9 (C-24), 23.3 (C-2), 21.1 (C-11), 19.1 (C-19), 18.2 (C-27), 17.5 (C-18), 16.6 (C-21).
(25R)-23-Acetyl-3,16-diacetoxy-22,23-pyran-cholesta-5,22-diene (20). ZnCl2 (1.0 g, 7.2 mmol, 6 eq.)
was added to a solution of diosgenine (1, 500 mg, 1.2 mmol, 1 eq.) in acetic anhydride (5 mL, 0.5 mmol,
0.4 eq.) and stirred at RT for 72 h. Water was added to the reaction mixture and extracted with EtOAc
(3 × 15 mL). The combined organic layer was washed with an aq NaHCO3 solution (30 mL), dried
(Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography on a
silica gel column (hexane/EtOAc/DCM, 9:1:1) yielding compound 20 as a white solid (620 mg, 96%):
Rf = 0.6 (hexane/EtOAc 4:1).1H-NMR (CDCl3) δ: 5.3 (d, J = 4.3Hz, 1H, H-6), 5.1 (dt, J1 = 5.9 Hz,
J2 = 4.9 Hz, 1H, H-16), 4.6 (dt, J = 12.9, 8.1 Hz, 1H, H-3), 4.0 (dd, J1 = 10.7 Hz, J2 = 4.7 Hz, 2H,
H-26), 2.9 (dd, J = 6.5 Hz, 1H, H-20,), 2.2 (s, 3H, 28-COCH3), 2.0 (s, 3H, 3-OCOCH3), 1.9 (s, 3H,
16-OCOCH3), 1.2 (d, J = 7.0 Hz, 3H, H-21,), 1.0 (s, 3H, H-19), 0.9 (s, 3H, H-18,), 0,8 (d, J = 6.3, 3H,
13
H-27); C-NMR (CDCl3) δ: 198.1 (C-27), 171.3 (C-22), 170.6 (16-OCOCH3), 170.4 (3-OCOCH3),
139.7 (C-5), 122.2 (C-6), 106.9 (C-23), 75.1 (C-16), 73.8 (C-3), 71.5 (C-26), 55.9 (C-17), 54.2 (C-14),
49.9 (C-9), 42.2 (C-13), 39.7 (C-12), 38.0 (C-4), 36.8 (C-1), 36.5 (C-10), 34.8 (C-15), 32.8 (C-20),
31.6 (C-24), 31.5 (C-7), 31.3 (C-8), 29.7 (COCH3), 28.4 (C-28), 27.8 (C-2), 22.2 (C-11), 21.2 (C-25),
21.3 (COCH3), 20.7 (C-19 C24), 19.3 (C-21), 19.2 (C-18).
(25R)-16-Acetoxy-4-cholesten-3,22-dione-26-al (21). DMSO (0.2 mL, 2.8 mmol, 93 eq.) was added
dropwise to a solution of (COCl)2 (0.1 mL, 2.3 mmol, 29 eq.) in DMC (5 mL) at −60 °C and the
resulting solution was stirred for 15 min. A solution of SN-1 (14.2 mg, 0.03 mmol, 1 eq.) in DMC (3 mL)
was added dropwise to this solution and stirred for 30 min. (iPr)2NEt (0.62 g, 4.8 mmol, 162 eq.) was
added dropwise, and the solution was warmed at RT for 1 h. The solution was diluted with water (10 mL)
and extracted with DCM (4 × 15 mL). The organic extracts were combined, washed with water (30 mL),
brine (30 mL), dried over Na2SO4, and concentrated in vacuo to yield 21 as a white solid. (8.2 mg,
58.1%): Rf = 0.6 (hexane/EtOAc 1:2). 1H-NMR (CDCl3) δ: 9.6 (s, 1H, CHO), 5.7 (s, 1H, H-4), 4.9 (dt,
J = 10.7, 5.9 Hz, 1H, H-16), 2.6 (dd, J = 16.4, 86 Hz, 2H, H-23), 2.0 (s, 3H, 16-OCOCH3), 1.2 (s, 3H,
13
H-19), 1.1 (d, J = 7.1 Hz, 3H, H-27), 1.0 (d, J = 7.1 Hz, 3H, H-21), 0.9 (s, 3H, H-18); C-NMR
(CDCl3) δ: 212.2 (C-22), 204.4 (C-26), 199.4 (C-3), 170.7 (16-OCOCH3), 170.6 (C-5), 124.0 (C-4),
78.4 (C-16), 57.7 (C-17), 53.4 (C-9), 52.8 (C-14), 47.9 (C-25), 45.6 (C-20), 43.6 (C-13), 39.3 (C-10),

Molecules 2013, 18
3372
38.7 (C-12), 38.5 (C-23), 35.6 (C-15), 34.9 (C-8), 34.1 (C-1), 33.9 (C-2), 32.6 (C-6), 31.7 (C-7), 23.9
(C-24), 21.2 (16-OCOCH3), 20.6 (C-11), 17.3 (C-19), 16.3 (C-18), 13.6 (C-21), 13.3 (C-27).
(25R)-16-Acetoxy-26-hydroxy-cholestan-3,22-dione (22). A mixture of SN-1 (20.9 mg, 0.04 mmol, 1 eq.)
and Pd/C 10% (1.0 mg, 10% mol, 0.1 eq.) in EtOAc (5 mL) was treated with hydrogen and stirred at
RT overnight. The reaction mixture was filtered through celite and the solvent was evaporated under
reduced pressure. The residue was purified by chromatography on a silica gel column (hexane/EtOAc
10:1) yielding compound 22 as a white solid (18.1 mg, 96.1%): Rf = 0.4 (hexane/AcOEt 2:1). 1H-NMR
(CDCl3) δ: 4.83 (dd, J1 =10.7, J2 = 5.9 Hz, 1H, H-16), 3.33 (d, , 2H, H-26), 2.4 (dd, , 2H, H-24), 2.0 (s,
3H, 28-COCH3), 1.1 (d, J = 7.1 Hz, 3H, H-21), 1.0 (s, 3H, H-19), 0.9 (s, 3H, H-18), 0.8 (d, J = 6.4 Hz,
13
3H, H-27); C-NMR (CDCl3) δ: 212.8 (C-22), 212.1 (C-3), 170.0 (16-OCOCH3), 77.4 (C-16), 65.7
(C-26), 56.7 (C-17), 52.2 (C-14), 51.9 (C-9), 51.7 (C-5), 46.4 (C-20), 42.6 (C-4), 42.5 (C-13), 38.4 (C-1),
38.2 (C-12), 38.1 (C-23), 38.0 (C-2), 37.0 (C-15), 36.7 (C-10), 33.8 (C-25), 33.5 (C-8), 30.1 (C-6),
29.6 (C-7), 25.0 (C-24), 21.2 (16-OCOCH3), 19.8 (C-19), 19.6 (C-18), 19.4 (C-11), 15.9 (C-27), 15.1
(C-21).
(25R)-16,26-Diacetoxy-4-cholesten-3,22-dione (23). Acetyl chloride (0.15 mL, 1.8 mmol, 450 eq.) was
added to a mixture of SN-1 (20.1 mg, 0.04 mmol, 1 eq.) in pyridine (2 mL) and the resulting solution
was stirred for 30 min at RT. Water was added to the reaction mixture and extracted with EtOAc
(3 × 15 mL). The combined organic layer was washed with an aq NaHCO3 solution (30 mL), dried
(Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography on a
silica gel column (hexane/EtOAc, 5:2) yielding compound 23 as a white solid (22.1 mg, 100%):
Rf = 0.6 (hexane/EtOAc 4:1). 1H-NMR (CDCl3) δ: 5.68 (s, 1H, H-4), 4.92 (dd, J1 = 10.7 Hz, J2 = 5.9 Hz,
1H, H-16), 3.55 (d, J = 10.7 Hz, 2H, H-26), 2.4 (dd, J = 16.4 Hz, 2H, H-23), 2.0 (s, 6H, COCH3), 1.2
(s, 3H, H-19), 1.1 (d, J = 7.1 Hz, 3H, H-21), 0.9 (s, 3H, H-18), 0.8 (d, J = 6.3 Hz, 3H, H-27).
13C-NMR (CDCl3) δ: 212.8 (C-22), 199.4 (C-3), 171.2 (24-OCOCH3), 170.6 (16-OCOCH3), 124.0
(C-4), 78.6 (C-16), 68.9 (C-26), 57.8 (C-17), 53.5 (C-14), 53.4 (C-9), 52.8 (C-5), 47.9 (C-20), 43.6 (C-4),
39.3 (C-13), 39.1 (C-1), 38.5 (C-12), 35.6 (C-23), 34.9 (C-2), 34.1 (C-15), 33.9 (C-10), 32.6 (C-25),
32.1 (C-8), 31.7 (C-6), 26.7 (C-7), 21.2 (C-24), 21.2 (16-OCOCH3), 20.8 (24-OCOCH3), 17.8 (C-19),
15.9 (C-27), 15.1 (C-21), 13.1 (C-18).
(25R)-16-Acetoxy-4-cholesten-3,22,26-triol (24). SN-1 (19.1 mg, 0.04 mmol, 1 eq.) in MeOH (5 mL)
was treated with NaBH4 (38.2 mg, 1 mmol, 25 eq.) and stirred at −15 °C for 2 h and then at RT
overnight. Water was added to the reaction mixture and extracted with DCM (2 × 15 mL). The
combined organic layer was washed with an aq NaHCO3 solution (30 mL), dried (Na2SO4) and
evaporated under reduced pressure. The residue was purified by chromatography on a silica gel
column (hexane/EtOAc 1:1) yielding compound 24 as a white solid (12 mg, 63%): Rf = 0.3
(hexane/AcOEt 1:1). M.p.: 144–146 °C. 1H-NMR (CDCl3) δ: 5.3 (d, J = 6.7 Hz, 1H, H-4), 5.0 (dt,
J1 = 10.7 Hz, J2 = 5.9 Hz, 1H, H-16), 4.1 (q, J = 6.7 Hz, 1H, H-3,), 3.5 (tq, J = 8.0, 7.0 Hz, 2H, H-22),
3.4 (d, J = 10.4 Hz, 2H, H-26), 2.0 (s, 3H, 16-OCOCH3), 1.2 (d, J = 7.1 Hz, 2H, H-21), 1.0 (s, 3H,
13
H-19), 0.8 (s, 3H, H-18); 0.7 (d, J = 7.1 Hz, 3H, H-27); C-NMR (CDCl3) δ: 170.7 (16-OCOCH3),
147.1 (C-5), 123.6 (C-4), 79.9 (C-16), 73.3 (C-22), 68.1 (C-26), 67.9 (C-3), 58.4 (C-17), 54.1 (C-9),

Molecules 2013, 18
3373
53.4 (C-14), 43.3 (C-13), 39.9 (C-12), 38.4 (C-20), 37.2 (C-10), 35.9 (C-25), 35.3 (C-8), 35.2 (C-15),
34.3 (C-1), 32.8 (C-6), 32.0 (C-7), 31.6 (C-24), 29.9 (C-23), 29.4 (C-2), 21.4 (C-18), 21.0 (16-
OCOCH3), 20.7 (C-11), 18.8 (C-19), 16.6 (C-27), 14.2 (C-21).
(25R)-16-Hydroxy-4-cholesten-3,22-dione-26-al (25). DMSO (0.2 mL, 2.8 mmol, 93 eq.) was added
dropwise to a solution of (COCl)2 (0.1 mL, 2.4 mmol, 47 eq.) in DCM (5 mL) at −60 °C and the
resulting solution was stirred for 15 min. A solution of SN-2 (21.5 mg, 0.05 mmol, 1 eq.) in DMC (3 mL)
was added dropwise to this solution and stirred for 30 min. (iPr)2NEt (0.62 g, 4.8 mmol, 162 eq.) was
added dropwise, and the solution was warmed at RT for 1 h. The solution was diluted with water (10 mL)
and extracted with DMC (4 × 15 mL). The organic extracts were combined, washed with water (30 mL),
brine (30 mL), dried over Na2SO4, and concentrated in vacuo to yield compound 25 as a white solid
1
(14.9 mg, 69.8%): Rf = 0.5 (hexane/EtOAc 1:2). H-NMR (CDCl3) δ: 9.6 (s, 1H, CHO), 5.7 (s, 1H,
H4), 2.9 (s, 1H, H-17), 2.6 (dd, J = 16.4 Hz, 2H, H-23), 1.1 (d, J = 7.1 Hz, 3H, H-21), 1.0 (d, J = 6.5 Hz,
13
3H, H-27), 0.8 (s, 3H, H-18); C-NMR (CDCl3) δ: 216.8 (C-16), 213.0 (C-22), 204.4 (C-26), 199.7
(C-3), 169.9 (C-5), 124.2 (C-4), 66.3 (C-17), 53.2 (C-9), 50.5 (C-14), 45.6 (C-25), 43.2 (C-20), 41.7
(C-13), 39.4 (C-15), 38.9 (C-10), 38.4 (C-12), 37.1 (C-23), 35.4 (C-1), 34.6 (C-8), 33.9 (C-2), 32.5 (C-6),
31.9 (C-7), 24.0 (C-24), 20.5 (C-11), 17.3 (C-19), 15.4 (C-18), 14.1 (C-21), 13.1 (C-27).
3.2. Biological Assays
3.2.1. In Vitro Antiplasmodial Activity
A 10 mg/mL stock solution was prepared. 2.0 mg of derivatives having greater than 95% purity (as
1
observed by TLC and H-NMR spectra) were dissolved in 200 μL pure DMSO. A 50 μL sample was
extracted from this solution and adjusted to 1,000 μL with RPMI-1640 without hypoxanthine until a
final 500 μg/mL concentration was reached. The P. falciparum FcB-2 (Colombia) and NF54 (The
Netherlands) strains were used for assessing anti-malarial activity.
Trager and Jensen’s method was used for culturing strains [24,25]. The methods described by
Desjardins et al. [26] were used for evaluating the structural analogs’ in vitro antiplasmodial activity,
with some modifications. 200 μL parasitized erythrocytes (1.0% parasitemia, 1.8% hematocrit) were
placed in 96-well plates preloaded with seven concentrations (100 µg/mL–3.12 µg/mL) of each
derivative in triplicate or with serial dilutions of chloroquine in positive control wells (3,753 nM up to
59 nM). 1.0 µCi/mL of [3H] hypoxanthine (MP Biomedicals, Santa Ana, CA, USA) was added to each
well and the plates were then incubated for 48 h at 37 °C in 5% CO2, 5% O2 in a balanced N2
atmosphere. Parasite DNA was harvested and radioactivity was determined by automatic TDCR liquid
scintillation counter plate (Chameleon, Hidex Oy, Finland). Experiments were repeated twice with two
or three replicates each. A nonlinear regression sigmoidal dose-response (variable slope) model was
used to estimate concentration inhibiting 50% growth (IC50) values for each derivative.
3.2.2. Cytotoxicity
HepG2-A16 human hepatoma cells (ATCC Hb-8065) were maintained in DMEM-F12
(Gibco, Carlsbad, CA, USA) supplemented with 10% bovine fetal serum (BFS) (Gibco) and
150 μg/mL penicillin/streptomycin (Sigma) at 37 °C in a 5% CO2 humidified atmosphere [27].

Molecules 2013, 18
3374
Steroidal derivatives’ cytotoxicity regarding the HepG2-A16 cell line was evaluated by colorimetric
test using 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT), as described by
Mosmann [28]. In brief, the cells were cultured in a 96-well flat-bottomed plate (2 × 105 cells/well in
100 μL complete medium) and incubated for 24 h at 37 °C in a 5% CO2 humidified atmosphere to
allow monolayer formation. An aliquot of each derivative dilution (100 μL, 1,000, 100, 10 and 1 μg/mL)
was then added to the wells in triplicate. The plates were incubated for another 48 h and then 30 μL MTT
(2 mg/mL) was added and the plates were incubated again for 4 h; DMSO (96%, 130 μL) was added
and plates incubated for a further 20 min at RT. The DMSO diluent agent was evaluated in complete
medium and negative controls (untreated cells) were included. Absorbance was measured at 550 nm
and statistical Prism software version 5.0 (GraphPad Software Inc., La Jolla, CA, USA) was used for
calculating toxic concentration (CC50). Amphotericin B was used as positive control in this assay.
3.2.3. The in Vivo Effects of Derivatives 14 and 18
Antimalarial activity was assessed in vivo in the P. berghei rodent malaria model according to
Peters’ 4-day suppressive test in P. berghei-infected (ANKA strain), 5–6 week-old Balb/C mice (males
and females) weighing 23 ± 5 g; parasitemia kinetics were evaluated following treatment [2]. The mice
were managed according to Colombian animal protection regulations (statute 84/1989), after approval
had been obtained from the Universidad de Antioquia’s Research Center’s (SIU) Ethics Committee.
Assays were carried out in the SIU animal housing’s testing room, coordinated by the Tropical
Diseases Program (PECET). The donor mice were anesthetized with a 5 mg/kg xylazine and 50 mg/kg
ketamine cocktail; blood was then collected via intracardiac route and 100 uL of 5 × 106 P. berghei
ANKA-parasitised parasitized erythrocytes per experimental mouse were inoculated. Mouse infection
was checked one day later by thin smear blood test and Giemsa staining. Batches of 5 animals per
group were then randomly distributed after infection and each group of mice received 100 μL of their
respective treatment via oral-gastric tube (day 0) [i.e., 100 mg/kg compound 2, derivative 14, 18,
negative control (standard suspending vehicle – SSV] or 5 mg/kg chloroquine in positive control. Mice
were treated again with the same dose given on day 0 after 24, 48 and 72 h. Each mouse had a thin
smear blood test on days 2, 4 and 5 (48, 96 and 120 h post-infection) and parasitemia was counted in
10,000 red blood cells (results expressed as percentage parasitized RBC). The difference between
control group mean value (taken as 100%) and those of the experimental groups was also calculated
and expressed as percent reduction using the following equation:
Inhibition = 100 − (mean percentage parasitemia treated/mean percentage parasitemia
control with SSV) × 100)
3.3. Computational Methods
Each compound’s geometry was optimized by B3LYP/6-31G(d) [29], using the Gaussian 03
software [30]. Electrostatic charges were calculated by fitting electrostatic potential to nuclear
positions, according to the CHELPG scheme [31].

Molecules 2013, 18
3375
3.3.1. CoMFA Details
Steric and electrostatic 3D fields were calculated by the CoMFA method using the interaction
between each catalyst and a probe atom. The probe atom had a specific charge and steric properties for
evaluating interaction energy at each point on a grid. The probe atom selected was a Sp3 C atom
having a + 1 point charge (i.e., Tripos C(3) force field atom) [32]; it was used to calculate Van der
Waals (steric) interactions. 3D-QSAR analysis was carried out using the CoMFA module [33] and
Sybyl 8.0 software [34].
3.3.2. Alignment Rule
All structures had to be aligned in a common framework when using 3D-QSAR for comparing the
26 compounds tested here [35]; the C atoms shared between fused A-B, B-C and C-D rings were
selected. The best grid spacing results were obtained with a 1.0 Å lattice spacing. Such late value was
considered an optimum value since higher precision in evaluating the 3D field by introducing a finer
grid would have resulted in an increase of so-called “brown noise” caused by the grid size sensitivity
of the statistical technique used for generating the models [36].
3.3.3. PLS Analysis
Partial least squares (PLS) analysis was performed for different combinations of field descriptors.
Autoscaling was used for PLS calculations regarding combined fields where each field was scaled to
give unit value variance. Software calculated each field’s standard deviation (SD) and divided each
value by the corresponding SD to assign the same prior importance to each variable in the analysis.
Leave one out (LOO) [37] cross-validated PLS analysis was initially used for determining statistical
model robustness and the optimal number of components. This involved examining the predictive
residual sum of squares (PRESS) and using the cross-validated regression coefficient (q2) as
guidelines. q2 was defined as:
N
2
PRESS =
(Y
 Ypred ,i )

(1)
(2)
obs,i
i1
q2 = 1 − PRESS/SSD
where Yobs,I and Ypred,I were actual and predicted dependent variables (respectively) and SSD the sum
of each dependent variable’s squared deviation from the mean of all dependent variables. Some
authors [38] have estimated that a greater than 0.3 q2 value has a 95% confidence limit. Usual drug
design practice considers a model having a q2 greater than 0.5 to be valid, i.e., halfway between perfect
predictions (q2 = 1.0) and no prediction at all (q2 = 0.0). The optimum number of components was
determined by minimizing PRESS while maximizing q2 values; the model having fewer components
was selected whenever an increase in q2 with an additional component was less than 5%. Adding more
components improved the fitting statistics but had two disadvantages: it complicated the model and
made it lose its predictive ability. A final model was obtained by non-cross-validated PLS analysis for
ascertaining the optimum number of components. The experimental activity values were transformed

Molecules 2013, 18
3376
to a logarithmic scale to improve data distribution, as recommended by usual QSAR practice [12]; the
transformation used was thus Log (1/IC50).
4. Conclusions
Only a few reports concerning steroids’ antiplasmodial activity could be found in the pertinent
literature, despite the fact some steroidal alkaloids having been shown to be active against malaria.
S. nudum steroidal compounds’ antiplasmodial activity, the good selectivity in vitro and it is well-
tolerated in early studies in a mouse model support this plant’s potential use in anti-malarial
medication and encourage attempts to look for new pharmacophores and more active compounds than
diosgenone. Diosgenone hemisynthesis from diosgenin is a good alternative for obtaining this
substance when establishing its effects in an infected-mouse model and determining its in vivo activity,
absorption and toxicity. Preparing other derivatives and synthesizing other compounds involving only
diosgenone A- and B-rings could yield new types of antimalarial substances, even though attempting
to obtain diosgenone from diosgenin in a single step has failed so far [21]. In short, a type of steroidal
saponin whose bioassays in an animal model have shown promissory activity against P. falciparum
has been reported for the first time here, though its structure should most likely be optimized to
achieve the best pharmacokinetic properties. Such types of molecule are obtainable from a cheap,
readily available, renewable raw material, such as diosgenin.
Acknowledgements
This study has been financed by Colciencias (Grant 1115-33-318854, RC-185-2006) and the
Universidad de Antioquia, Colombia (CODI-Sustainability strategy 2011-2012 UdeA). The authors
would like to thank Ana Maria Mesa for isolating the S. nudum steroidal compounds, Lina Zuluaga for
performing the toxicity assays and Sara Robledo and Alejandro Daza from PECET for animal care and
handling and the therapeutic efficacy assays using Balb/C mice.
References
1. WHO. World malaria report 2011. WHO Global Malaria Programme; WHO Press: Geneva,
Switzerland, 2011; p. 246.
2. Fidock, D.A.; Rosenthal, P.J.; Croft, S.L.; Brun, R.; Nwaka, S. Antimalarial drug discovery:
Efficacy models for compound screening. Nat. Rev. Drug Discov. 2004, 3, 509–520.
3. Blair, S.; Carmona-Fonseca, J.; Pineros, J.G.; Rios, A.; Alvarez, T.; Alvarez, G.; Tobon, A.
Therapeutic efficacy test in malaria falciparum in Antioquia, Colombia. Malar. J. 2006, 5, 1–14.
4. Itokawa, H.; Morris-Natschke, S.L.; Akiyama, T.; Lee, K.H. Plant-derived natural product
research aimed at new drug discovery. Nat. Med. (Tokyo) 2008, 62, 263–280.
5. Saez, J.; Cardona, W.; Espinal, D.; Blair, S.; Mesa, J.; Boar, M.; Jossang, A. Five new steroids
from Solanum nudum. Tetrahedron 1998, 54, 10771–10778.
6. Pabon, A.; Carmona, J.; Maestre, A.; Camargo, M.; Blair, S. Inhibition of P. falciparum by
steroids isolated from Solanum nudum. Phytother. Res. 2002, 16, 59–62.

Molecules 2013, 18
3377
7. Blair, S.; Mesa, J.; Correa, A.; Saez, J. Apertura del anillo F de al diosgenona y actividad
antimalárica in vitro de los productos de reacción. Rev. Col. Quím. 2001, 30, 97–107.
8. Devkota, K.P.; Lenta, B.N.; Choudhary, M.I.; Naz, Q.; Fekam, F.B.; Rosenthal, P.J.; Sewald, N.
Cholinesterase inhibiting and antiplasmodial steroidal alkaloids from Sarcococca hookeriana.
Chem. Pharm. Bull. 2007, 55, 1397–1401.
9. Alvarez, G.; Pabon, A.; Carmona, J.; Blair, S. Evaluation of clastogenic potential of the
antimalarial plant Solanum nudum. Phytother. Res. 2004, 18, 845–848.
10. Pabon, A.; Blair, S.; Carmona, J.; Zuleta, M.; Saez, J. Evaluation of the mutagenicity of
antimalarial products isolated from Solanum nudum (Solanaceae). Pharmazie 2003, 58, 263–267.
11. Londono, B.; Arango, E.; Zapata, C.; Herrera, S.; Saez, J.; Blair, S.; Carmona-Fonseca, J. Effect
of Solanum nudum Dunal (Solanaceae) steroids on hepatic trophozoites of Plasmodium vivax.
Phytother. Res. 2006, 20, 267–273.
12. Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Merz, A.; Rognan, D. Recommendations to
CoMFA Studies and 3D QSAR Publications. Quant. Struct. Act. Relat. 1994, 13, 1–3.
13. Cramer, R.D., III; DePriest, S.A.; Patterson, D.E.; Hecht, P. The Developing Practice of
Comparative Molecular Field Analysis. In 3D QSAR in Drug Design: Theory, Methods and
Applications; Kubinyi, H., Ed.; Kluwer-ESCOM: Leiden, The Netherlands, 1993; pp. 443–485.
14. Wold, S.; Ruhe, A.; Wold, H.; Dunn, W.J., III. The Collinearity problem in linear regression. The
partial least squares approach to generalized inverses. SIAM J. Sci. Stat. Comput. 1984, 5, 735–743.
15. Cardona, D.; Quiñones, W.; Torres, F.; Robledo, S.; Vélez, I.; Cruz, V.; Notario, R.; Echeverri, F.
Leishmanicidal activity of withajardins and acnistins. An experimental and computational study.
Tetrahedron 2006, 62, 6822–6829.
16. Jacobus, J.M.; van der Linden, P.W.; Hilberink, C.M. P.; Kronenburg, J.K.; Gerardus, J.K.
Investigation of the Moffatt-Swern Oxidation in a Continuous Flow Microreactor System.
Org. Process Res. Dev. 2008, 12, 911–920.
17. Sakac, M.; Gakovic, A.; Stojanovic, S.; Djurendic, E.; Kojic, V.; Bogdanovic, G.; Gasi, K.P.
Synthesis and biological evaluation of a series of A,B-ring modified 16,17-secoandrostane
derivatives. Bioorg. Med. Chem. 2008, 36, 128–132.
18. Rincon, S.; del Rio, R.E.; Sandoval-Ramirez, J.; Meza-Reyes, S.; Montiel-Smith, S.; Fernandez, M.;
Farfan R.; Santillan, R. A new route for the preparation of the 22,23-dioxocholestane side chain
from diosgenin and its application to the stereocontrolled construction of the 22R,23S-diol
function. Tetrahedron 2006, 62, 2594–2602.
19. Lingnau, A.; Margos, G.; Maier, W.A.; Seitz, H.M. The effects of hormones on the
gametocytogenesis of Plasmodium falciparum in vitro. Appl Parasitol. 1993, 34, 153–160.
20. Quan, H.J.; Koyanagi, J.; Ohmori, K.; Uesato, S.; Tsuchido, T.; Saito, S. Preparations of
heterospirostanols and their pharmacological activities. Eur. J. Med. Chem. 2002, 37, 659–669.
21. Almeida, M.L.; Kocovsky, P.; Backvall, J.E. Ruthenium-Catalyzed Oppenauer-Type Oxidation of
3beta-Hydroxy Steroids. A Highly Efficient Entry into the Steroidal Hormones with 4-En-3-one
Functionality. J. Org. Chem. 1996, 61, 6587–6590.
22. Ferchaud, V.; Courcoux, P.; Le Bizec, B.; Monteau, F.; Andre, F. Enzymatic hydrolysis of
conjugated steroid metabolites: search for optimum conditions using response surface
methodology. Analyst 2000, 125, 2255–259.

Molecules 2013, 18
3378
23. Lee, S.S.; Yan, J.L.; Lin, G.Y.; Wang, K.C. Microbial transformation of dihydrosarsasapogenin
with Mycobacterium sp. J. Nat. Prod. 1998, 61, 275–278.
24. Trager, W. Cultivation of parasites in vitro. Am. J. Trop. Med. Hyg. 1978, 27, 216–222.
25. Trager, W.; Jensen, J.B. Human malaria parasites in continuous culture. Science 1976, 193, 673–675.
26. Desjardins, R.E.; Canfield, C.J.; Haynes, J.D.; Chulay, J.D. Quantitative assessment of
antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents
Chemother. 1979, 16, 710–718.
27. Davies, C.S.; Suhrbier, A.S.; Winger, L.A.; Sinden, R.E. Improved techniques for the culture of
the liver stages of Plasmodium berghei and their relevance to the study of causal prophylactic
drugs. Acta Leiden 1989, 58, 97–113.
28. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to
proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63.
29. Becke, A. Density-functional exchange-energy approximation with correct asymptotic behavior.
Phys. Rev. A 1998, 38, 3098–3100.
30. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.;
Montgomery, J.J.A.; Vreven, T.; Kudin, K.N.; Burant, J.C.; et al. Gaussian 03, Revision C.02;
Gaussian, Inc.: Pittsburgh, PA, USA, 2004.
31. Curt, M.B.; Kenneth, B.W. Determining atom-centered monopoles from molecular electrostatic
potentials. The need for high sampling density in formamide conformational analysis.
J. Comput. Chem. 1990, 11, 361–373.
32. Clark, M.H.; Cramer, R.D.; Opdenbosch, N.V. Validation of the general purpose tripos 5.2 force
field. J. Comp. Chem. 1989, 10, 982–1012.
33. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1.
Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959–5967.
34. Zhong, H.; Bowen, J.P. GALAHAD pharmacophore modeling for drug discovery. J. Am.
Chem. Soc. 2007, 129, 5780.
35. Martin, Y.C.; Kim, K.-H.; Lin, C.T. Comparative Molecular Field Analysis: COMFA. In
Advances in Quantitative Structure-Property Relationships; Charton, M., Ed.; JAI Press,
Greenwich, CT, USA, 1996; Volume 1, pp. 1–52.
36. Rannar, S.; Lindgren, F.; Geladi, P.; Wold, S. A PLS Kernel Algorithm for Data Sets with Many
Variables and Fewer Objects. Part 1: Theory and Algorithm. J. Chemometr. 1994, 8, 111–125.
37. Cramer, R.; Bunce, J.; Patterson, D.; Frank, I. Crossvalidation, boot strapping and partial least
squares compared with multiple regression in conventional QSAR studies. Quant. Struct. Act. Relat.
1988, 7, 18–25.
38. Clark, M.; Cramer, I.R. The probability of chance correlation using partial least squares (PLS).
Quant. Struct. Act. Relat. 1993, 12, 137–145.
Sample Availability: Samples of the compounds 1–20 are available from the authors.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).